BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

Innovus Pharma Provides Regulatory And Commercial Update On The Label Indication For Zestra® For Female Sexual Desire Disorder ("FSDD") From Health Canada


1/10/2014 9:22:14 AM

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

LA JOLLA, Calif., Jan. 10, 2014 (GLOBE NEWSWIRE) -- Innovus Pharmaceuticals, Inc., ("Innovus Pharma" or the "Company") www.innovuspharma.com (OTCBB:INNV) today announced that its newly acquired wholly-owned subsidiary, Semprae Laboratories, Inc. ("Semprae") is working with Health Canada to finalize the packaging for the indication for its topical over the counter ("OTC") Natural Health Product, Zestra®, for the temporary improved sexual desire in women suffering from female sexual desire disorder" ("FSDD"). The first Canadian Product License approval for this indication was obtained by Semprae in July 2012, but never applied to the Zestra® label. The Company is expected to finalize the new packaging for this product with Health Canada with the approved FSDD indication within 90 days. In addition, the Company is filing to expand the indication to women with Female Sexual Arousal Disorder (FSAD) due to statistically significant improvement in arousal and Female Sexual Function Index (FSFI) scores observed in its large clinical trial in women with FSAD.

Help employers find you! Check out all the jobs and post your resume.


Read at GlobeNewswire

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES